Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Pressure BioSciences, Inc. (OTCQB: ... in the development and sale of high pressure-based ... market, today announced that Professor Ruedi Aebersold ... highly reproducible, and robust method to allow – ... analysis on small needle biopsy samples by mass ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
(Date:10/26/2014)... The report "Protective Coatings Market by Resin Type, ... Forecast to 2019", defines and segments the global protective ... and value generated. The protective coatings consumption is projected ... KT by 2019, at a CAGR of 9.52% during ... and 22 figures spread through 219 slides and in-depth ...
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
Breaking Biology Technology:Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... PhD, Further Strengthens Kendle,s Global ... Regulatory Affairs Organization, ... ), a,leading, global full-service clinical research organization, today,announced that ... Affairs Consultant specializing in providing regulatory affairs,guidance to the ...
... CORNER, N.J., Aug. 10 Reliant Pharmaceuticals,Inc. today announced ... S-1,with the Securities and Exchange Commission for an initial ... that Reliant,will sell newly issued common stock and that ... of Reliant,s common stock. Goldman, Sachs & Co. ...
... has Initiated a Phase II study of R1507 ... for the Treatment of ... today that its partner, Roche has initiated a Phase II,clinical study ... antibody was created by Genmab under the company,s,agreement with Roche and ...
Cached Biology Technology:Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 2Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 3Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:10/28/2014)... Individual differences in moving activity in a novel ... to angling, according to an experimental study completed ... Finnish Game and Fisheries Research Institute. The study ... groups and authentic angling trials to analyse if ... trout reared in traditional and enriched hatchery rearing ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
(Date:10/27/2014)... day, about a third of blacks hold onto sodium ... an hour after the stress that raised their pressure ... know how chronic mental stress, obesity, and inflammation conspire ... the best ways to treat it. , "We ... – these patients have increased damage to their hearts, ...
Breaking Biology News(10 mins):Fish 'personality' linked to vulnerability to angling 2'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
... one of many important crop species that is unsuited ... used to work with crops. Researchers, reporting in the ... first high-throughput forward and reverse genetics tool for the ... breeders around the world.. Researchers from the INRA ...
... ambitious expedition led by scientists at Scripps Institution of ... little-known islands in the central Pacific Ocean has yielded ... threats from human activities. The exploration of four ... approximately a thousand miles south of Hawaii, has produced ...
... The reductionist goal of cell biology is to ... do this, one needs to quantify molecular concentrations ... execute and regulate various complex processes. For ... characterized by highly localized, transient component processes, the ...
Cached Biology News:Scientists unravel the genetic coding of the pea 2Scripps expedition provides new baseline for coral reef conservation 2Scripps expedition provides new baseline for coral reef conservation 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
... DNA Modification Kit contains reagents required to ... sample. In the bisulfite reaction, all unmethylated ... to uracils, while 5-methylcytosines remain unaltered. Thus, ... differ depending on whether the DNA is ...
Biology Products: